TY - JOUR
T1 - Racial differences in rates of aortic valve replacement in patients with severe aortic stenosis
AU - Yeung, Michael
AU - Kerrigan, Jimmy
AU - Sodhi, Sandeep
AU - Huang, Pei Hsiu
AU - Novak, Eric
AU - Maniar, Hersh
AU - Zajarias, Alan
N1 - Funding Information:
This work was supported by Mentors in Medicine , Washington University School of Medicine.
PY - 2013/10/1
Y1 - 2013/10/1
N2 - Racial disparities exist in the treatment of many cardiovascular diseases. Aortic valve replacement (AVR) is the only treatment for aortic stenosis (AS) that improves patient symptoms and survival. To date, no studies have compared the rate of AVR among different races. The records of patients with an aortic valve area <1 cm2 by echocardiography diagnosed between January 2004 and May 2010 at Barnes-Jewish Hospital were reviewed retrospectively. Patients were stratified by race. Of the 880 patients analyzed, 10% were African American (AA), and 90% were European American (EA). AA more frequently had hypertension (82% vs 67%, p <0.01), diabetes mellitus (45% vs 32%, p = 0.02), chronic kidney disease (28% vs 17%, p = 0.01), and end stage renal disease (18% vs 2%, p <0.001). AA underwent AVR less frequently than EA (39% vs 53%, p = 0.02) and refused intervention more often (33% vs 20%, p = 0.04). When treated, AA and EA had similar 3-year survival (49% [38 to 60] vs 50% [45 to 54], p = 0.31). Identification of the factors associated with treatment refusal would further our ability to counsel patients on the decision to pursue AVR.
AB - Racial disparities exist in the treatment of many cardiovascular diseases. Aortic valve replacement (AVR) is the only treatment for aortic stenosis (AS) that improves patient symptoms and survival. To date, no studies have compared the rate of AVR among different races. The records of patients with an aortic valve area <1 cm2 by echocardiography diagnosed between January 2004 and May 2010 at Barnes-Jewish Hospital were reviewed retrospectively. Patients were stratified by race. Of the 880 patients analyzed, 10% were African American (AA), and 90% were European American (EA). AA more frequently had hypertension (82% vs 67%, p <0.01), diabetes mellitus (45% vs 32%, p = 0.02), chronic kidney disease (28% vs 17%, p = 0.01), and end stage renal disease (18% vs 2%, p <0.001). AA underwent AVR less frequently than EA (39% vs 53%, p = 0.02) and refused intervention more often (33% vs 20%, p = 0.04). When treated, AA and EA had similar 3-year survival (49% [38 to 60] vs 50% [45 to 54], p = 0.31). Identification of the factors associated with treatment refusal would further our ability to counsel patients on the decision to pursue AVR.
UR - https://www.scopus.com/pages/publications/84884416837
U2 - 10.1016/j.amjcard.2013.05.030
DO - 10.1016/j.amjcard.2013.05.030
M3 - Article
C2 - 23791013
AN - SCOPUS:84884416837
SN - 0002-9149
VL - 112
SP - 991
EP - 995
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 7
ER -